Rimonabant

Corbus Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Corporate Update

Retrieved on: 
Tuesday, November 7, 2023
Rimonabant, NSCLC, Food, Biomarker, Doctor of Philosophy, CB1, Breast cancer, University of Virginia Cancer Center, SITC, The Obesity Society, Head, CSPC, FACP, Human, Therapeutic index, Cleavage, Yale School of Medicine, Society for Immunotherapy of Cancer, Mouse, DIO, Immunotherapy, University, Hand, Investment, Patient, Monoclonal antibody, Food and Drug Administration Amendments Act of 2007, Plasma, Conference, Liraglutide, Development, ADC, Brain, Insulin resistance, Society, AACR, IND, Manuscript, Poster, MMAE, Semaglutide, Tumor microenvironment, Carcinoma, Mab, Neck, Medical imaging, Vaccine, Soft drink, Pharmaceutical industry, Corbus, MD, Obesity

“The third quarter was a productive period for Corbus as data was presented for each of our three programs at relevant scientific conferences” said Yuval Cohen, Ph.D., Chief Executive Officer of Corbus.

Key Points: 
  • “The third quarter was a productive period for Corbus as data was presented for each of our three programs at relevant scientific conferences” said Yuval Cohen, Ph.D., Chief Executive Officer of Corbus.
  • Finally, we presented the first ever comprehensive data on CRB-913, our highly peripherally restricted cannabinoid type-1 receptor (CB1) inverse agonist.
  • Early clinical experience will be shared in Q1 2024, which will coincide with the initiation of a U.S./EU trial by Corbus.
  • Corbus presented two posters at the 38th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) held on November 1 - 5, 2023.

Corbus Pharmaceuticals Announces Publication of Data for its Novel Cannabinoid Type-1 Receptor Inverse Agonist in a Pre-Clinical Model of Obesity Along with Presentations at Obesity Week 2023

Retrieved on: 
Tuesday, October 17, 2023
DIO, Partnership, Plasma, Morning Star, Rimonabant, Insulin resistance, Manuscript, Human, Weight loss, CB1, Mouse, The Obesity Society, Conference, Dietary supplement, Pharmaceutical industry, Tirzepatide, Semaglutide, Obesity, Liraglutide

“These data point to the potential of CRB-913, both as a monotherapy in combination with incretin therapies,” said Yuval Cohen, Ph.D., Chief Executive Officer of Corbus.

Key Points: 
  • “These data point to the potential of CRB-913, both as a monotherapy in combination with incretin therapies,” said Yuval Cohen, Ph.D., Chief Executive Officer of Corbus.
  • CRB-913 demonstrated markedly enhanced plasma exposure and markedly reduced brain levels compared to the first generation CB1 inverse agonist rimonabant.
  • Concomitantly, improvements were observed in body fat content, leptinemia, insulin resistance, liver triglycerides, liver fat deposits and liver histology.
  • Investigators concluded that CRB-913, in combination with incretin analogs, could potentially deliver meaningful improvements in obesity and related conditions.

Try The Strongest THCV, CBN, CBG and CBD Gummies For Free With Rare Cannabinoid Company's Holiday Offer

Retrieved on: 
Friday, December 10, 2021
People, Sleep, United States National Library of Medicine, CBG, COVID-19, Taste, Appetite, Rimonabant, Health, Exercise, Terpene, Cannabis, Seizure, THCV, Directory, Honey, Pain, CBDA, Inflammation, Diet, National Center for Biotechnology Information, Holiday, Nicotine, THC, Research, Autism, CB1, CBDV, National library, CBC, Cancer, Parkinson's disease, CBN, Creative, Well-order, Entrepreneurship, Nausea, CBGA, Plant, Weight loss, British Journal of Pharmacology, Cannabinol, Cannabinoid, National Center for Complementary and Integrative Health, FDA, Sale, Muscular dystrophy, Friends, Relaxation, Nursing, New Year, Quarantine, Weight gain, Dietary supplement, Perfume, Pharmaceutical industry

Rare Cannabinoid Company's new high potency cannabinoid gummies hit the mark for healthy gifts that taste good too.

Key Points: 
  • Rare Cannabinoid Company's new high potency cannabinoid gummies hit the mark for healthy gifts that taste good too.
  • The brand is now offering free variety packets so customers can try their THCV gummies (for energy and appetite suppression), CBN gummies (for restful sleep), CBG gummies (to ease discomfort) and CBD gummies (for calm and balance).
  • The brand's other new cannabinoid gummies are also among the strongest, if not the strongest, on the market, and offer targeted relief.
  • The THCV gummies, CBN gummies, CBG gummies, and CBD gummies are all very strong.

Corbus Pharmaceuticals Reports Fourth Quarter and Year-End 2019 Financial Results

Retrieved on: 
Thursday, March 12, 2020
Drugs, Chemical compounds, Branches of biology, Cannabinoids, Chloroarenes, Pyrazoles, Anorectics, Piperidines, Rimonabant, Agonist

In November, the Company announced completion of enrollment in the Phase 2b study evaluating lenabasum in 426 individuals with CF.

Key Points: 
  • In November, the Company announced completion of enrollment in the Phase 2b study evaluating lenabasum in 426 individuals with CF.
  • Topline data expected in the summer of 2020 following RESOLVE-1 topline results.
  • Corbus second drug, CRB-4001, is a peripherally restricted CB1 inverse agonist, designed to avoid the central nervous system side effects seen with rimonabant.
  • Financial Results for Fourth Quarter and Year-End December 31, 2019
    Revenue from awards and licenses was $2.6 million for the three months ended December 31, 2019, compared to $1.9 million in the comparable period in 2018.